Videos

Richard Nowak, MD, MS, discusses remaining questions surrounding inebilizumab in generalized myasthenia gravis, including long-term durability, biomarker development, and the need for real-world and expanded population data.

Mitzi Joi Williams, MD, sits down with sleep specialist Shantel Branson, MD, to discuss how sleep impacts brain health, memory, mood, and long-term neurologic well-being.

At CMSC 2026, the neuroimmunologist and director at OhioHealth MS Center, discussed results from the phase 3 FENhance 1 and 2 studies, highlighting significant reductions in relapse rates and robust MRI outcomes. [WATCH TIME: 3 minutes]

The neurologist at Orlando Health discussed findings from an analysis of cladribine tablets in patients aged 50 years and older with relapsing multiple sclerosis presented at CMSC 2026. [WATCH TIME: 7 minutes]

Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, examine the expanding clinical trial landscape for stem cell therapies in Parkinson disease and the programs leading development efforts.

The research neuropsychologist at Mount Sinai Rehabilitation Hospital outlined hallmark patterns of cognitive impairment in multiple sclerosis at the 2026 CMSC Annual Meeting. [WATCH TIME: 6 minutes]

From patient questions to clinical trial referrals, this episode highlights practical strategies for counseling individuals interested in stem cell-based therapies for Parkinson disease.

A clinical research coordinator at SunnyBrook Health Sciences Centre, explained key factors of the computerized cognitive training program that contributed to cognitive improvement. [WATCH TIME: 3 minutes]

The neurologist at St. Michael's Hospital shared findings presented at CMSC 2026 from a large dataset on preconception ocrelizumab exposure among women with multiple sclerosis. [WATCH TIME: 5 minutes]

A Parkinson’s patient shares how apomorphine injections and extended-release amantadine smooth OFF time, reduce dyskinesia, yet lingering episodes persist.

Learn how apomorphine injections and extended-release amantadine smooth Parkinson’s OFF time, reduce dyskinesia, and restore mornings.

Neurologists Roger Barker, MBBS, MRCP, PhD, FMedSci, and Claire Henchcliffe, MD, DPhil, discuss the development, goals, and educational value of ISSCR's new stem cell medicine course for Parkinson disease.

At CMSC 2026, Jamie Lynn Sigler, an actress and patient advocate, shared her perspective on living with multiple sclerosis, emphasizing informed decision-making and treatment consistency. [WATCH TIME: 7 minutes]

Neurology News Network for the week ending May 30, 2026. [WATCH TIME: 4 minutes]

The director of the Stony Broke MS Comprehensive Care Center reviewed late-breaking subgroup data evaluating high-efficacy therapy in patients with highly active relapsing multiple sclerosis and discussed the evolving role of early intervention. [WATCH TIME: 5 minutes]

Learn how clinicians set CIDP treatment goals: gradual strength gains, managing residual deficits, IVIG tapering, and defining remission.

Sam Amin, MD, reviews the design of the recent phase 3 fenfluramine study in CDKL5 deficiency disorder, highlighting patient eligibility, baseline seizure burden, concomitant medication use, and key efficacy endpoints.

Objective CID

Richard Nowak, MD, MS, discusses how inebilizumab fits within the current gMG treatment landscape, highlighting its upstream CD19-targeted mechanism and sustained clinical benefit compared with other biologic strategies.

Katherine B. Peters, MD, PhD, shares practical insights on prescribing vorasidenib, including patient education, safety monitoring, and how clinicians can confidently integrate this targeted therapy into routine care.

Parkinson’s meds start wearing off; a patient and caregiver reveal how stress, digestion, and honest doctor talks improve symptom control.

A Parkinson’s patient shares early medication choices, dosing challenges, and side effects—plus why sticking to treatment helps him stay active at work and home.

Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 4 minutes]

FcRn inhibitors emerge for CIDP relapse prevention, yet biomarker gaps and careful transitions from IVIG shape who benefits.

Explore subcutaneous immunoglobulin for CIDP: HYQVIA and HYZENTRA data, who benefits most, and how it compares with IVIG side effects.

Richard Nowak, MD, MS, discusses pharmacodynamic findings from the MINT trial, highlighting rapid and sustained B-cell depletion with inebilizumab and the current limitations of biomarkers in predicting clinical response.

The discussion opens with a clinical overview of CDKL5 deficiency disorder, focusing on the severe seizure burden, associated developmental complications, and the ongoing limitations of current antiseizure treatment strategies.

Katherine B. Peters, MD, PhD, discusses how INDIGO (NCT04164901) findings may shift practice toward earlier treatment in IDH-mutant glioma, even after gross total resection, while highlighting ongoing questions around patient selection and long-term management.

The chief medical executive at Marcus Neuroscience Institute discussed the evolving role of AI, advanced imaging, and precision therapeutics in neurology presented at Baptist Health’s 2026 Brain & Spine Symposium. [WATCH TIME: 5 minutes]

The nurse practitioner at the University of Miami and the president of the IOMSN discussed advice for younger colleagues, misconceptions about neurology nursing, and more. [WATCH TIME: 10 minutes]